%0 Journal Article
%T Botulinum toxin treatment for hypersalivation in antiİ\NMDA receptor encephalitis
%A Han Gil Seo
%A Jinİ\Sun Jun
%A Kon Chu
%A Soonİ\Tae Lee
%J Archive of "Annals of Clinical and Translational Neurology".
%D 2017
%R 10.1002/acn3.467
%X Hypersalivation is one of the intractable symptoms of antiİ\Nİ\methylİ\dİ\aspartate receptor (NMDAR) encephalitis. While anticholinergic medications partially improve the hypersalivation, they can aggravate the autonomic dysfunctions associated with antiİ\NMDAR encephalitis. Thus, we investigated the efficacy and safety of botulinum toxin type A injection on hypersalivation refractory to anticholinergics in six patients with antiİ\NMDAR encephalitis. Hypersalivation was wellİ\controlled without remarkable adverse reaction over 16 weeks after botulinum toxin type A, although two patients were reinjected at 12 weeks due to reaggravation of hypersalivation. Our findings suggest that botulinum toxin type A might be a better choice than anticholinergics for management of hypersalivation in patients with antiİ\NMDAR encephalitis
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682120/